Evidence check: CYP1A2 in the context of blood sugar

CYP1A2 is a phase I enzyme primarily known for metabolizing caffeine and certain drugs. A direct, clinically meaningful link to blood sugar regulation is not well established. Some observational studies suggest that slow caffeine metabolizers (due to CYP1A2 variants) may experience slightly altered glucose tolerance, likely mediated by caffeine's acute effect on insulin sensitivity. However, the effects are small, inconsistent, and not proven causal. A DNA test for CYP1A2 alone is not actionable for blood sugar management. Established factors like diet, exercise, sleep, and possibly continuous glucose monitoring are far more relevant. The evidence level is mechanistic/unclear; marketing claims labeling CYP1A2 a 'blood sugar gene' are overblown.